Nirmatrelvir/Ritonavir (PaxlovidTM) – what a pharmacist needs to know

  • $0.00 incl. GST for PSNZ members
  • $180.00 incl. GST for non-members

About the product

Go to Registration page

Completing this course will provide participants with the evidence, indications for and mechanisms of Paxlovid in their treatment of COVID-19 in the community. They will refresh their knowledge of CYP450 interactions and how these impact on the use of Paxlovid. The criteria for and supply restrictions, as well as private supply of Paxlovid are discussed. The use of case studies allow participants to apply their knowledge in practice. Finally, extra resources and patient information is available. This course was updated in November 2023.

About this learning module;

This learning consists of a 40-minute presentation (recorded in April 2022) and supplementary readings. This education course has no formal assessment.

This learning can be used for your annual recertification requirements -

Presented By:

Lauren Smith, Professional Practice Fellow at the School of Pharmacy, University of Otago, and member of the New Zealand Antimicrobial Stewardship & Infection Pharmacist Expert Group (NAMSIPEG)with a special interest in antibiotic stewardship.

Additional content supplied was developed by PSNZ Education, Professional Development and Training staff.

Upon completion of the course, participants should be able to:

  • Describe the mechanism and action of Paxlovid
  • Explain the pharmacology and pharmacokinetics of Paxlovid in relation to drug/drug interactions
  • Explain the mechanisms of CYO450 interactions
  • Describe the contraindications for Paxlovid
  • Identify the current recommendations for Paxlovid in pregnancy and breastfeeding
  • Evaluate current evidence for Paxlovid in the treatment of COVID-19
  • Apply knowledge to answer queries or evaluate prescriptions
  • Describe the eligibility criteria and supply process for Paxlovid in NZ
  • Locate and supply patient information about Paxlovid.

Sponsored By

PSNZ Education, Professional Development and Training would like to acknowledge Pfizer for their financial support for this course allowing us to make it free for our members. The information delivered has been developed independently of their support.

    Register now